Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI).

Background: Community acquired pneumonia (CAP) is a major cause of morbidity, hospitalization, and mortality worldwide. Management of CAP for many patients requires rapid initiation of empirical antibiotic treatment, based on the spectrum of activity of available antimicrobial agents and evidence on local antibiotic resistance. Few data exist on the severity profile and treatment of hospitalized CAP patients in Eastern and Central Europe and the Middle East, in particular on use of moxifloxacin (Avelox®), which is approved in these regions.

[Comparative assessment of fluoroquinolones efficacy in the treatment of patients with infectious exacerbation of chronic obstructive bronchitis].

Moxyfloxacinum in a dose of 400 mg daily in tablets over 5 days proved to have good results in 92,7% of patients with infectious exacerbation of chronic obstructive bronchitis type I. Cyprofloxacin in a dose of 500 mg every 12 hours over 7 days had positive effects in 78,6%. Thus, the using of fluoroquinolones in patients with infectious exacerbation of chronic obstructive bronchitis type I gives sufficiently good results.

[Lung contusions: diagnostics, treatment stages].

The authors studied a group of patients with simple thorax injury, contusion of lungs and injury of thorax frame (1225 patients), who had been refused to be hospitalized to specialized poly-trauma departments due to some reasons. 34% of these patients had fractures of ribs, thorax and rib arcs and 15% of them had two-sided traumas. The group of the patients with simple thorax injury and lung contusion, but without injuries of thorax frame, consisted of 63% of the patients, who addressed for an aid at first hours after accidents.

[Role of endoscopic sanitation in the treatment of chronic obstructive pulmonary diseases].

The results of conducted investigations and experience of bronchoscopy (more than 1500 per year) confirm that use of endoscopic sanitation in treatment of chronic obstructive pulmonary diseases sufficiently improves the function of external breathing, speeds-up recovery of patient and extends remission. We consider that chronic obstructivepulmonary disease (COPD) is an indication for medical-and-diagnostic fibrobronchoscopy.